Mallika Singh
New York City Department of Health and Mental Hygiene(US)University of Washington(US)University of the Free State(ZA)Revolution Medicines (United States)(US)Jamaica Hospital(US)Cancer Research Center(US)21st Century Technologies (United States)(US)Disco (Germany)(DE)New York University(US)Seattle University(US)Case Western Reserve University(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Cancer Research and Treatments, PI3K/AKT/mTOR signaling in cancer, Cancer-related Molecular Pathways, Melanoma and MAPK Pathways
Most-Cited Works
- → High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response(2015)1,424 cited
- → Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis(2006)979 cited
- → RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers(2018)411 cited
- → Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression(2008)332 cited
- → Crystal Structure of BMP-9 and Functional Interactions with Pro-region and Receptors(2005)302 cited
- → Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy(2024)280 cited